{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:13:46Z","timestamp":1793798026669,"version":"4.6.1"},"reference-count":202,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,2,23]],"date-time":"2020-02-23T00:00:00Z","timestamp":1582416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1A2A2A07001035"],"award-info":[{"award-number":["2017R1A2A2A07001035"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Neurodegenerative diseases are a large group of neurological disorders with diverse etiological and pathological phenomena. However, current therapeutics rely mostly on symptomatic relief while failing to target the underlying disease pathobiology. G-protein-coupled receptors (GPCRs) are one of the most frequently targeted receptors for developing novel therapeutics for central nervous system (CNS) disorders. Many currently available antipsychotic therapeutics also act as either antagonists or agonists of different GPCRs. Therefore, GPCR-based drug development is spreading widely to regulate neurodegeneration and associated cognitive deficits through the modulation of canonical and noncanonical signals. Here, GPCRs\u2019 role in the pathophysiology of different neurodegenerative disease progressions and cognitive deficits has been highlighted, and an emphasis has been placed on the current pharmacological developments with GPCRs to provide an insight into a potential therapeutic target in the treatment of neurodegeneration.<\/jats:p>","DOI":"10.3390\/cells9020506","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T04:21:26Z","timestamp":1582604486000},"page":"506","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":126,"title":["G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative Disorders and Associated Cognitive Deficits"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4707-3488","authenticated-orcid":false,"given":"Shofiul","family":"Azam","sequence":"first","affiliation":[{"name":"Department of Applied Life Science &amp; Integrated Bioscience, Graduate School, Konkuk University, Chungju 27478, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md. Ezazul","family":"Haque","sequence":"additional","affiliation":[{"name":"Department of Applied Life Science &amp; Integrated Bioscience, Graduate School, Konkuk University, Chungju 27478, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8216-1171","authenticated-orcid":false,"given":"Md.","family":"Jakaria","sequence":"additional","affiliation":[{"name":"Department of Applied Life Science &amp; Integrated Bioscience, Graduate School, Konkuk University, Chungju 27478, Korea"},{"name":"The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Hee","family":"Jo","sequence":"additional","affiliation":[{"name":"Department of Applied Life Science &amp; Integrated Bioscience, Graduate School, Konkuk University, Chungju 27478, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Su","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Integrated Bioscience &amp; Biotechnology, College of Biomedical and Health Science, and Research Institute of Inflammatory Disease (RID), Konkuk University, Chungju 27478, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7041-1524","authenticated-orcid":false,"given":"Dong-Kug","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Applied Life Science &amp; Integrated Bioscience, Graduate School, Konkuk University, Chungju 27478, Korea"},{"name":"Department of Integrated Bioscience &amp; Biotechnology, College of Biomedical and Health Science, and Research Institute of Inflammatory Disease (RID), Konkuk University, Chungju 27478, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/WAD.0000000000000034","article-title":"Diagnostic criteria for vascular cognitive disorders: A VASCOG statement","volume":"28","author":"Sachdev","year":"2014","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI200317522","article-title":"Neurodegeneration: What is it and where are we?","volume":"111","author":"Przedborski","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Jakaria, M., Azam, S., Cho, D.-Y., Haque, M.E., Kim, I.-S., and Choi, D.-K. (2019). The Methanol Extract of Allium cepa L. Protects Inflammatory Markers in LPS-Induced BV-2 Microglial Cells and Upregulates the Antiapoptotic Gene and Antioxidant Enzymes in N27-A Cells. Antioxidants, 8.","DOI":"10.3390\/antiox8090348"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Jakaria, M., Azam, S., Jo, S.-H., Kim, I.-S., Dash, R., and Choi, D.-K. (2019). Potential Therapeutic Targets of Quercetin and Its Derivatives: Its Role in the Therapy of Cognitive Impairment. J. Clin. Med., 8.","DOI":"10.3390\/jcm8111789"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jgr.2018.01.001","article-title":"Emerging signals modulating potential of ginseng and its active compounds focusing on neurodegenerative diseases","volume":"43","author":"Jakaria","year":"2019","journal-title":"J. Ginseng Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"33601","DOI":"10.18632\/oncotarget.26035","article-title":"Active ginseng components in cognitive impairment: Therapeutic potential and prospects for delivery and clinical study","volume":"9","author":"Jakaria","year":"2018","journal-title":"Oncotarget"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"101223","DOI":"10.1016\/j.redox.2019.101223","article-title":"Taurine and its analogs in neurological disorders: Focus on therapeutic potential and molecular mechanisms","volume":"24","author":"Jakaria","year":"2019","journal-title":"Redox Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.coph.2017.02.001","article-title":"The role of GPCRs in neurodegenerative diseases: Avenues for therapeutic intervention","volume":"32","author":"Huang","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_9","first-page":"f4827","article-title":"Clinical review. Frontotemporal dementia","volume":"347","author":"Warren","year":"2013","journal-title":"BMJ Clin. Res. Ed."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/nmt.11.9","article-title":"Management of frontotemporal dementia: Targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options","volume":"1","author":"Jicha","year":"2011","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_11","first-page":"11","article-title":"Intra-familial clinical heterogeneity due to FTLD-U with TDP-43 proteinopathy caused by a novel deletion in progranulin gene (PGRN)","volume":"22","author":"Gabryelewicz","year":"2010","journal-title":"J. Alzheimers Dis. JAD"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuint.2016.09.005","article-title":"G-protein coupled receptors as therapeutic targets for neurodegenerative and cerebrovascular diseases","volume":"101","author":"Guerram","year":"2016","journal-title":"Neurochem. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: New agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"De Oliveira, P.G., Ramos, M.L.S., Amaro, A.J., Dias, R.A., and Vieira, S.I. (2019). Gi\/o-Protein Coupled Receptors in the Aging Brain. Front. Aging Neurosci., 11.","DOI":"10.3389\/fnagi.2019.00089"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrn1365","article-title":"Genes and ligands for odorant, vomeronasal and taste receptors","volume":"5","author":"Mombaerts","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.biotechadv.2013.08.017","article-title":"An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases","volume":"31","author":"Heng","year":"2013","journal-title":"Biotechnol. Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mol.117.111062","article-title":"G protein-coupled receptors as targets for approved drugs: How many targets and how many drugs?","volume":"93","author":"Sriram","year":"2018","journal-title":"Mol. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1146\/annurev-pharmtox-011613-135943","article-title":"The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication","volume":"54","author":"Masuram","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bcp.2018.02.016","article-title":"The G protein-coupled receptors deorphanization landscape","volume":"153","author":"Laschet","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1091\/mbc.e06-12-1080","article-title":"5-hydroxytryptamine 4 receptor activation of the extracellular signal-regulated kinase pathway depends on Src activation but not on G protein or beta-arrestin signaling","volume":"18","author":"Barthet","year":"2007","journal-title":"Mol. Biol. Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"R47","DOI":"10.1530\/JOE-18-0532","article-title":"The impact of anorexigenic peptides in experimental models of Alzheimer\u2019s disease pathology","volume":"240","author":"Bencze","year":"2019","journal-title":"J. Endocrinol."},{"key":"ref_22","first-page":"a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Frosch","year":"2011","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase inhibitors: Pharmacology and toxicology","volume":"11","year":"2013","journal-title":"Curr. Neuropharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ana.24001","article-title":"The therapeutics of Alzheimer\u2019s disease: Where we stand and where we are heading","volume":"74","author":"Selkoe","year":"2013","journal-title":"Ann. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/aps.2009.24","article-title":"Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases","volume":"30","author":"Dong","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00002018-200831070-00003","article-title":"Memantine for the treatment of Alzheimer\u2019s disease: Tolerability and safety data from clinical trials","volume":"31","author":"Farlow","year":"2008","journal-title":"Drug Saf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"948","DOI":"10.7150\/ijbs.6426","article-title":"Glutamate, glutamate receptors, and downstream signaling pathways","volume":"9","author":"Willard","year":"2013","journal-title":"Int. J. Biol. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1756-6606-7-40","article-title":"Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer\u2019s disease","volume":"7","author":"Hamilton","year":"2014","journal-title":"Mol. Brain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.neuron.2013.06.036","article-title":"Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein","volume":"79","author":"Um","year":"2013","journal-title":"Neuron"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuropharm.2014.05.013","article-title":"SSP-002392, a new 5-HT4 receptor agonist, dose-dependently reverses scopolamine-induced learning and memory impairments in C57Bl\/6 mice","volume":"85","author":"Lo","year":"2014","journal-title":"Neuropharmacology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.neuropharm.2012.06.007","article-title":"Stimulation of serotonin 2A receptors facilitates consolidation and extinction of fear memory in C57BL\/6J mice","volume":"64","author":"Zhang","year":"2013","journal-title":"Neuropharmacology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3233\/JAD-2008-14110","article-title":"The pathology of \u201cvascular dementia\u201d: A critical update","volume":"14","author":"Jellinger","year":"2008","journal-title":"J. Alzheimers Dis. JAD"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0006-8993(96)00400-3","article-title":"Relationship between cholinergic dysfunction and discrimination learning disabilities in Wistar rats following chronic cerebral hypoperfusion","volume":"729","author":"Tanaka","year":"1996","journal-title":"Brain Res."},{"key":"ref_34","first-page":"709","article-title":"Involvement of dopamine D1 receptors of the hippocampal dentate gyrus in spatial learning and memory deficits in a rat model of vascular dementia","volume":"69","author":"Wan","year":"2014","journal-title":"Die Pharm. Int. J. Pharm. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s12035-014-8736-3","article-title":"Activation of GABA B receptors ameliorates cognitive impairment via restoring the balance of HCN1\/HCN2 surface expression in the hippocampal CA1 area in rats with chronic cerebral hypoperfusion","volume":"50","author":"Li","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"ref_36","first-page":"289","article-title":"Hippocampal 5-HT1A receptor and spatial learning and memory","volume":"6","author":"Saling","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1093\/brain\/awp069","article-title":"Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition","volume":"132","author":"Elliott","year":"2009","journal-title":"Brain"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.tips.2008.07.001","article-title":"A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory","volume":"29","author":"King","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S1474-4422(05)70223-4","article-title":"Frontotemporal dementia","volume":"4","author":"Neary","year":"2005","journal-title":"Lancet Neurol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/brain\/awr171","article-title":"The effects of oxytocin on social cognition and behaviour in frontotemporal dementia","volume":"134","author":"Jesso","year":"2011","journal-title":"Brain J. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fnins.2015.00335","article-title":"Oxytocin and vasopressin: Linking pituitary neuropeptides and their receptors to social neurocircuits","volume":"9","author":"Baribeau","year":"2015","journal-title":"Front. Neurosci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1126\/science.1158668","article-title":"Oxytocin, Vasopressin, and the Neurogenetics of Sociality","volume":"322","author":"Donaldson","year":"2008","journal-title":"Science"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.mcn.2006.01.006","article-title":"Oxytocin and estrogen promote rapid formation of functional GABA synapses in the adult supraoptic nucleus","volume":"31","author":"Theodosis","year":"2006","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ana.20365","article-title":"Glucose metabolism and serotonin receptors in the frontotemporal lobe degeneration","volume":"57","author":"Franceschi","year":"2005","journal-title":"Ann. Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00213-007-0992-8","article-title":"Imbalance of a serotonergic system in frontotemporal dementia: Implication for pharmacotherapy","volume":"196","author":"Bowen","year":"2008","journal-title":"Psychopharmacology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0091-3057(02)00826-2","article-title":"NMDA-induced phosphorylation and regulation of mGluR5","volume":"73","author":"Alagarsamy","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00429-014-0978-3","article-title":"In vivo characterization of metabotropic glutamate receptor type 5 abnormalities in behavioral variant FTD","volume":"221","author":"Leuzy","year":"2016","journal-title":"Brain Struct. Funct."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/cercor\/bhi087","article-title":"Bursting of prefrontal cortex neurons in awake rats is regulated by metabotropic glutamate 5 (mGlu5) receptors: Rate-dependent influence and interaction with NMDA receptors","volume":"16","author":"Homayoun","year":"2005","journal-title":"Cereb. Cortex"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","author":"Kalia","year":"2015","journal-title":"Lancet"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jnc.13691","article-title":"The clinical symptoms of Parkinson\u2019s disease","volume":"13","author":"Sveinbjornsdottir","year":"2016","journal-title":"J. Neurochem."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"29835","DOI":"10.18632\/oncotarget.8104","article-title":"Emerging preclinical pharmacological targets for Parkinson\u2019s disease","volume":"7","author":"More","year":"2016","journal-title":"Oncotarget"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.0b013e3181f39d0e","article-title":"Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis","volume":"75","author":"Aarsland","year":"2010","journal-title":"Neurology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney multicenter study of Parkinson\u2019s disease: The inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Hisahara, S., and Shimohama, S. (2011). Dopamine Receptors and Parkinson\u2019s Disease. Int. J. Med. Chem., 2011.","DOI":"10.1155\/2011\/403039"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/sj.npp.1301073","article-title":"Differential roles of dopamine D1 and D2 receptors in the nucleus accumbens in attentional performance on the five-choice serial reaction time task","volume":"32","author":"Pezze","year":"2007","journal-title":"Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/mds.25857","article-title":"The neurobiological basis of cognitive impairment in Parkinson\u2019s disease","volume":"29","author":"Halliday","year":"2014","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/01.wnl.0000249130.63615.cc","article-title":"Differences in neuropathologic characteristics across the Lewy body dementia spectrum","volume":"67","author":"Ballard","year":"2006","journal-title":"Neurology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1212\/WNL.0b013e3181ab2b58","article-title":"Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET","volume":"73","author":"Shimada","year":"2009","journal-title":"Neurology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/syn.21823","article-title":"5-HT1B receptor imaging and cognition: A positron emission tomography study in control subjects and Parkinson\u2019s disease patients","volume":"69","author":"Varrone","year":"2015","journal-title":"Synapse"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1017\/S1355617706060723","article-title":"Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS)","volume":"12","author":"Benedict","year":"2006","journal-title":"J. Int. Neuropsychol. Soc. JINS"},{"key":"ref_61","first-page":"585","article-title":"Processing speed in relapsing-remitting multiple sclerosis: The role played by the depressive symptoms","volume":"55","author":"Lubrini","year":"2012","journal-title":"Rev. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1037\/0894-4105.13.4.546","article-title":"Depression in multiple sclerosis: Relationship to working memory capacity","volume":"13","author":"Arnett","year":"1999","journal-title":"Neuropsychology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrneurol.2014.139","article-title":"The link between multiple sclerosis and depression","volume":"10","author":"Feinstein","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.genhosppsych.2007.08.002","article-title":"Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis","volume":"30","author":"Ehde","year":"2008","journal-title":"Gen. Hosp. Psychiatry"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1523\/JNEUROSCI.11-06-01649.1991","article-title":"Chronic quinolinic acid lesions in rats closely resemble Huntington\u2019s disease","volume":"11","author":"Beal","year":"1991","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0028-3908(00)00079-4","article-title":"Selective blockade of metabotropic glutamate receptor subtype 5 is neuroprotective","volume":"39","author":"Bruno","year":"2000","journal-title":"Neuropharmacology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.brainres.2004.06.005","article-title":"The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington\u2019s disease","volume":"1019","author":"Schiefer","year":"2004","journal-title":"Brain Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fnins.2013.00114","article-title":"Dopamine imbalance in Huntington\u2019s disease: A mechanism for the lack of behavioral flexibility","volume":"7","author":"Chen","year":"2013","journal-title":"Front. Neurosci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"12218","DOI":"10.1073\/pnas.0502698102","article-title":"Unraveling a role for dopamine in Huntington\u2019s disease: The dual role of reactive oxygen species and D2 receptor stimulation","volume":"102","author":"Charvin","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.nbd.2007.07.028","article-title":"Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo","volume":"29","author":"Charvin","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0149-7634(99)00067-6","article-title":"5-HT system and cognition","volume":"23","author":"Meneses","year":"1999","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3109\/07853890008998828","article-title":"Role of serotonin in memory impairment","volume":"32","author":"Buhot","year":"2000","journal-title":"Ann. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.coph.2011.01.004","article-title":"5-HT6 receptor and cognition","volume":"11","author":"Codony","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.neuropharm.2008.06.061","article-title":"An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function","volume":"55","author":"Fone","year":"2008","journal-title":"Neuropharmacology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/B978-0-12-385902-0.00002-4","article-title":"5-HT6 receptor memory and amnesia: Behavioral pharmacology\u2013learning and memory processes","volume":"Volume 96","author":"Meneses","year":"2011","journal-title":"International Review of Neurobiology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"41293","DOI":"10.1038\/srep41293","article-title":"A new serotonin 5-HT6 receptor antagonist with procognitive activity\u2014Importance of a halogen bond interaction to stabilize the binding","volume":"7","author":"Medina","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7160","DOI":"10.1021\/jm5003952","article-title":"Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer\u2019s disease","volume":"57","author":"Pardo","year":"2014","journal-title":"J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/alzrt169","article-title":"5-HT 6 receptors and Alzheimer\u2019s disease","volume":"5","year":"2013","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1358\/dof.2014.39.2.2103730","article-title":"The 5-HT6 receptor antagonism approach in Alzheimer\u2019s disease","volume":"39","author":"Marazziti","year":"2014","journal-title":"Drugs Future"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00213-011-2518-7","article-title":"The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats","volume":"220","author":"Mohler","year":"2012","journal-title":"Psychopharmacology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40263-016-0399-3","article-title":"Serotonin 5-HT6 Receptor Antagonists in Alzheimer\u2019s Disease: Therapeutic Rationale and Current Development Status","volume":"31","author":"Ferrero","year":"2017","journal-title":"CNS Drugs"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40120-018-0095-y","article-title":"5HT6 Antagonists in the Treatment of Alzheimer\u2019s Dementia: Current Progress","volume":"7","author":"Andrews","year":"2018","journal-title":"Neurol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2165\/00003495-200767010-00004","article-title":"Serotonergic drugs: Effects on appetite expression and use for the treatment of obesity","volume":"67","author":"Halford","year":"2007","journal-title":"Drugs"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2174\/1567205013666161108105005","article-title":"AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models","volume":"14","author":"Ivachtchenko","year":"2017","journal-title":"Curr. Alzheimer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3233\/JAD-151146","article-title":"AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders","volume":"53","author":"Ivachtchenko","year":"2016","journal-title":"J. Alzheimers Dis. JAD"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1021\/acs.molpharmaceut.5b00830","article-title":"AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer\u2019s Disease","volume":"13","author":"Ivachtchenko","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S1474-4422(14)70232-7","article-title":"Idalopirdine for Alzheimer\u2019s disease: Written in the stars","volume":"13","author":"Schneider","year":"2014","journal-title":"Lancet Neurol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000088494","article-title":"Donepezil in vascular dementia: Combined analysis of two large-scale clinical trials","volume":"20","author":"Roman","year":"2005","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2174\/156720510791383831","article-title":"Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer\u2019s disease","volume":"7","author":"Hunter","year":"2010","journal-title":"Curr. Alzheimer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/gps.2562","article-title":"SB-742457 and donepezil in Alzheimer disease: A randomized, placebo-controlled study","volume":"26","author":"Dixon","year":"2011","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_91","first-page":"23","article-title":"Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer\u2019s disease","volume":"1","author":"Watson","year":"2015","journal-title":"Alzheimers Dement."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","article-title":"Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer\u2019s disease: A randomised, double-blind, placebo-controlled study","volume":"372","author":"Doody","year":"2008","journal-title":"Lancet"},{"key":"ref_93","first-page":"P250","article-title":"Safety, tolerability and pharmacokinetics of SUVN-502\u2014A 5-HT6 receptor antagonist, first in human phase-1 Single Ascending Dose (SAD) study","volume":"5","author":"Nirogi","year":"2009","journal-title":"Alzheimers Dement. J. Alzheimers Assoc."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jpba.2017.04.005","article-title":"Development and validation of sensitive LC-MS\/MS method for the quantification of SUVN-502 and its metabolite and its application for first in human pharmacokinetic study","volume":"145","author":"Nirogi","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1021\/acs.jmedchem.6b01662","article-title":"Discovery and Development of 1-[(2-Bromophenyl) sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl) methyl]-1 H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer\u2019s Disease","volume":"60","author":"Nirogi","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000445873","article-title":"Agomelatine improves apathy in frontotemporal dementia","volume":"16","author":"Callegari","year":"2016","journal-title":"Neurodegener. Dis."},{"key":"ref_97","first-page":"1","article-title":"EPA-1197\u2013Agomelatine for treating apathy in alzheimer\u2019s disease","volume":"29","author":"Karaiskos","year":"2014","journal-title":"Eur. Psychiatry"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/JCP.0000000000000404","article-title":"Agomelatine for depression in Parkinson disease: Additional effect on sleep and motor dysfunction","volume":"35","author":"Avila","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Biskup, C.S., Sanchez, C.L., Arrant, A., Van Swearingen, A.E., Kuhn, C., and Zepf, F.D. (2012). Effects of acute tryptophan depletion on brain serotonin function and concentrations of dopamine and norepinephrine in C57BL\/6J and BALB\/cJ mice. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035916"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1177\/0269881108099424","article-title":"The effects of acute tryptophan depletion on affective behaviour and cognition in Brown Norway and Sprague Dawley rats","volume":"24","author":"Jans","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/BF00441950","article-title":"Biochemical aspects of tryptophan depletion in primates","volume":"98","author":"Young","year":"1989","journal-title":"Psychopharmacology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s002130050845","article-title":"Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation","volume":"141","author":"Riedel","year":"1999","journal-title":"Psychopharmacology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.neubiorev.2009.03.006","article-title":"Effects of acute tryptophan depletion on memory, attention and executive functions: A systematic review","volume":"33","author":"Mendelsohn","year":"2009","journal-title":"Neurosci. Biobehav. Rev."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/1097-0142(20001015)89:8<1739::AID-CNCR14>3.0.CO;2-F","article-title":"The effect of less than definitive care on breast carcinoma recurrence and mortality","volume":"89","author":"Lash","year":"2000","journal-title":"Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1017\/S0007114514003754","article-title":"Chronic treatment with a tryptophan-rich protein hydrolysate improves emotional processing, mental energy levels and reaction time in middle-aged women","volume":"113","author":"Mohajeri","year":"2015","journal-title":"Br. J. Nutr."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1179\/1476830511Y.0000000032","article-title":"Effects of a diet integration with an oily emulsion of DHA-phospholipids containing melatonin and tryptophan in elderly patients suffering from mild cognitive impairment","volume":"15","author":"Rondanelli","year":"2012","journal-title":"Nutr. Neurosci."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1503\/jpn.140120","article-title":"Vortioxetine: A meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder","volume":"40","author":"Pae","year":"2015","journal-title":"J. Psychiatry Neurosci."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.eurpsy.2009.05.010","article-title":"Acute citalopram administration may disrupt contextual information processing in healthy males","volume":"25","author":"Almeida","year":"2010","journal-title":"Eur. Psychiatry J. Assoc. Eur. Psychiatr."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e1800422","DOI":"10.1002\/mnfr.201800422","article-title":"Dietary Galacto-Oligosaccharides and Resistant Starch Protect Against Altered CB1 and 5-HT1A and 2A Receptor Densities in Rat Brain: Implications for Preventing Cognitive and Appetite Dysfunction During a High-Fat Diet","volume":"62","author":"Yu","year":"2018","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_110","first-page":"490","article-title":"The occurrence, distribution and physiological role of catecholamines in the nervous system","volume":"11","author":"Carlsson","year":"1959","journal-title":"Pharmacol. Rev."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/archneur.61.5.641","article-title":"The Neurobiology of Dopamine Signaling","volume":"61","author":"Girault","year":"2004","journal-title":"Arch. Neurol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.neuron.2015.12.029","article-title":"Dopamine Does Double Duty in Motivating Cognitive Effort","volume":"89","author":"Westbrook","year":"2016","journal-title":"Neuron"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nrn.2016.57","article-title":"Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression","volume":"17","author":"Grace","year":"2016","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/pr.115.010512","article-title":"Dopamine\u2019s Actions in Primate Prefrontal Cortex: Challenges for Treating Cognitive Disorders","volume":"67","author":"Arnsten","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1007\/s12035-017-0758-1","article-title":"The DRD2 Taq1A A1 Allele May Magnify the Risk of Alzheimer\u2019s in Aging African-Americans","volume":"55","author":"Blum","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"119704","DOI":"10.1016\/j.biomaterials.2019.119704","article-title":"Lipid-based nanodelivery approaches for dopamine-replacement therapies in Parkinson\u2019s disease: From preclinical to translational studies","volume":"232","author":"Karthivashan","year":"2020","journal-title":"Biomaterials"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF01406329","article-title":"Hypothalamic neuropeptides and memory","volume":"75","author":"Jolles","year":"1985","journal-title":"Acta Neurochir."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cortex.2018.11.031","article-title":"Dopamine guides competition for cognitive control: Common effects of haloperidol on working memory and response conflict","volume":"113","author":"Fallon","year":"2019","journal-title":"Cortex"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am. J. Psychiatry"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuropharm.2019.01.003","article-title":"Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention","volume":"148","author":"Marshall","year":"2019","journal-title":"Neuropharmacology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nlm.2013.12.010","article-title":"The endocannabinoid system: An emotional buffer in the modulation of memory function","volume":"112","author":"Morena","year":"2014","journal-title":"Neurobiol. Learn. Mem."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Campolongo, P., Ratano, P., Manduca, A., Scattoni, M.L., Palmery, M., Trezza, V., and Cuomo, V. (2012). The endocannabinoid transport inhibitor AM404 differentially modulates recognition memory in rats depending on environmental aversiveness. Front. Behav. Neurosci., 6.","DOI":"10.3389\/fnbeh.2012.00011"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1073\/pnas.0900835106","article-title":"Endocannabinoids in the rat basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory","volume":"106","author":"Campolongo","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pbb.2018.05.012","article-title":"Examination of the effects of cannabinoid ligands on decision making in a rat gambling task","volume":"170","author":"Ferland","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s00213-015-3942-x","article-title":"Persistent effects of chronic \u03949-THC exposure on motor impulsivity in rats","volume":"232","author":"Irimia","year":"2015","journal-title":"Psychopharmacology"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3940(02)00936-9","article-title":"Anandamide and noladin ether prevent neurotoxicity of the human amyloid-beta peptide","volume":"332","author":"Milton","year":"2002","journal-title":"Neurosci. Lett."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejphar.2003.08.026","article-title":"Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade","volume":"477","author":"Mazzola","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.neuroscience.2016.05.012","article-title":"Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer\u2019s disease","volume":"329","author":"Manuel","year":"2016","journal-title":"Neuroscience"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.neuropharm.2012.05.013","article-title":"WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-gamma pathway","volume":"63","author":"Fakhfouri","year":"2012","journal-title":"Neuropharmacology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.brainres.2009.05.098","article-title":"The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages","volume":"1283","author":"Tolon","year":"2009","journal-title":"Brain Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.neurobiolaging.2012.06.011","article-title":"Activation of the CB2 receptor system reverses amyloid-induced memory deficiency","volume":"34","author":"Wu","year":"2013","journal-title":"Neurobiol. Aging"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.tips.2006.11.001","article-title":"Cannabinoid CB2 receptor: A new target for controlling neural cell survival?","volume":"28","author":"Romero","year":"2007","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/glia.20838","article-title":"Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington\u2019s disease","volume":"57","author":"Sagredo","year":"2009","journal-title":"Glia"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1093\/brain\/awp239","article-title":"Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2019s disease excitotoxicity","volume":"132","author":"Palazuelos","year":"2009","journal-title":"Brain J. Neurol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00001756-200305060-00007","article-title":"Effects of cannabinoids in the rat model of Huntington\u2019s disease generated by an intrastriatal injection of malonate","volume":"14","author":"Bizat","year":"2003","journal-title":"Neuroreport"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/mol.115.101980","article-title":"Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease","volume":"89","author":"Laprairie","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"29789","DOI":"10.1038\/srep29789","article-title":"VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington\u2019s disease","volume":"6","author":"Navarrete","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bcp.2018.07.049","article-title":"Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1(G93A) transgenic mice, an experimental model of amyotrophic lateral sclerosis","volume":"157","author":"Bellido","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Colangelo, C., Shichkova, P., Keller, D., Markram, H., and Ramaswamy, S. (2019). Cellular, Synaptic and Network Effects of Acetylcholine in the Neocortex. Front. Neural Circuits, 13.","DOI":"10.3389\/fncir.2019.00024"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbr.2010.02.025","article-title":"Localisation of pre- and postsynaptic cholinergic markers in the human brain","volume":"221","author":"Wevers","year":"2011","journal-title":"Behav. Brain Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0006-3223(00)01011-8","article-title":"Overview of nicotinic receptors and their roles in the central nervous system","volume":"49","author":"Dani","year":"2001","journal-title":"Biol. Psychiatry"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.bcp.2007.06.015","article-title":"Nicotinic receptors as CNS targets for Parkinson\u2019s disease","volume":"74","author":"Quik","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/pr.110.003269","article-title":"\u03b16\u03b22* and \u03b14\u03b22* Nicotinic Acetylcholine Receptors as Drug Targets for Parkinson\u2019s Disease","volume":"63","author":"Quik","year":"2011","journal-title":"J. Pharmacol. Rev."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"8772","DOI":"10.1523\/JNEUROSCI.0901-14.2014","article-title":"Striatal Cholinergic Neurotransmission Requires VGLUT3","volume":"34","author":"Nelson","year":"2014","journal-title":"J. Neurosci."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nn.2984","article-title":"GABAergic circuits mediate the reinforcement-related signals of striatal cholinergic interneurons","volume":"15","author":"English","year":"2011","journal-title":"Nat. Neurosci."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.neuroscience.2011.08.066","article-title":"Dopamine release in the basal ganglia","volume":"198","author":"Rice","year":"2011","journal-title":"Neuroscience"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/nn769","article-title":"Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum","volume":"4","author":"Zhou","year":"2001","journal-title":"Nat. Neurosci."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1742-2094-9-98","article-title":"\u03b17 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation","volume":"9","author":"Liu","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neuroscience.2017.05.019","article-title":"Neuroprotective effect of the alpha 7 nicotinic receptor agonist PHA 543613 in an in vivo excitotoxic adult rat model","volume":"356","author":"Page","year":"2017","journal-title":"Neuroscience"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ajpath.2013.10.010","article-title":"alpha7 Nicotinic receptor agonist enhances cognition in aged 3xTg-AD mice with robust plaques and tangles","volume":"184","author":"Medeiros","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/psyg.12189","article-title":"Behavioural effects of PNU-282987 and stress in an animal model of Alzheimer\u2019s disease","volume":"17","author":"Vicens","year":"2017","journal-title":"Psychogeriatr. Off. J. Jpn. Psychogeriatr. Soc."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00213-003-1668-7","article-title":"AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors","volume":"172","author":"Selbach","year":"2004","journal-title":"Psychopharmacology"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1124\/jpet.106.118976","article-title":"The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxa mide improves working and recognition memory in rodents","volume":"321","author":"Boess","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_155","first-page":"463","article-title":"Mitochondrial protection by the mixed muscarinic\/sigma1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Abeta25-35 peptide-injected mice, a nontransgenic Alzheimer\u2019s disease model","volume":"8","author":"Lahmy","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.neuropharm.2010.10.022","article-title":"Metabotropic glutamate receptors: From the workbench to the bedside","volume":"60","author":"Nicoletti","year":"2011","journal-title":"Neuropharmacology"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: Physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2174\/1567205011666140812115423","article-title":"Metabotropic glutamate receptor 5 in Down\u2019s syndrome hippocampus during development: Increased expression in astrocytes","volume":"11","author":"Iyer","year":"2014","journal-title":"Curr. Alzheimer Res."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fnmol.2018.00414","article-title":"Metabotropic Glutamate Receptors in Glial Cells: A New Potential Target for Neuroprotection?","volume":"11","author":"Spampinato","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.neuroscience.2013.08.054","article-title":"Enhancement of long-term depression by soluble amyloid \u03b2 protein in rat hippocampus is mediated by metabotropic glutamate receptor and involves activation of p38MAPK, STEP and caspase-3","volume":"253","author":"Chen","year":"2013","journal-title":"Neuroscience"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.neuron.2010.04.029","article-title":"Deleterious Effects of Amyloid \u03b2 Oligomers Acting as an Extracellular Scaffold for mGluR5","volume":"66","author":"Renner","year":"2010","journal-title":"Neuron"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1124\/mol.110.067488","article-title":"Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer\u2019s Disease: Selective Activation of mGlu2 Receptors Amplifies \u03b2-Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is Neuroprotective","volume":"79","author":"Caraci","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/aps.2011.210","article-title":"Orphan G protein-coupled receptors (GPCRs): Biological functions and potential drug targets","volume":"33","author":"Tang","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"S271","DOI":"10.1016\/j.biopsych.2017.02.1078","article-title":"669. GPR52 Agonists Represent a Novel Approach to Treat Cognitive Deficits Associated with Schizophrenia","volume":"81","author":"Grottick","year":"2017","journal-title":"Boil. Psychiatry"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fncel.2018.00258","article-title":"Importance of GPCR-Mediated Microglial Activation in Alzheimer\u2019s Disease","volume":"12","author":"Haque","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"309ra164","DOI":"10.1126\/scitranslmed.aab3492","article-title":"Loss of GPR3 reduces the amyloid plaque burden and improves memory in Alzheimer\u2019s disease mouse models","volume":"7","author":"Huang","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1084\/jem.20171320","article-title":"Gpr158 mediates osteocalcin\u2019s regulation of cognition","volume":"214","author":"Khrimian","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s42003-018-0106-7","article-title":"Expression map of 78 brain-expressed mouse orphan GPCRs provides a translational resource for neuropsychiatric research","volume":"1","author":"Ehrlich","year":"2018","journal-title":"Commun. Biol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1126\/science.1160649","article-title":"The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons","volume":"323","author":"Thathiah","year":"2009","journal-title":"Science"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"e33273","DOI":"10.7554\/eLife.33273","article-title":"Orphan receptor GPR158 controls stress-induced depression","volume":"7","author":"Sutton","year":"2018","journal-title":"eLife"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Komatsu, H., Maruyama, M., Yao, S., Shinohara, T., Sakuma, K., Imaichi, S., Chikatsu, T., Kuniyeda, K., Siu, F.K., and Peng, L.S. (2014). Anatomical transcriptome of G protein-coupled receptors leads to the identification of a novel therapeutic candidate GPR52 for psychiatric disorders. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090134"},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Valverde, O., Celerier, E., Baranyi, M., Vanderhaeghen, P., Maldonado, R., Sperlagh, B., Vassart, G., and Ledent, C. (2009). GPR3 receptor, a novel actor in the emotional-like responses. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0004704"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/hipo.22747","article-title":"A putative lysophosphatidylinositol receptor GPR55 modulates hippocampal synaptic plasticity","volume":"27","author":"Hurst","year":"2017","journal-title":"Hippocampus"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1006\/bbrc.2000.2829","article-title":"An evolutionarily conserved G-protein coupled receptor family, SREB, expressed in the central nervous system","volume":"272","author":"Matsumoto","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/gtc.12378","article-title":"Identification and molecular docking studies for novel inverse agonists of SREB, super conserved receptor expressed in brain","volume":"21","author":"Yanai","year":"2016","journal-title":"Genes Cells"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S1567-133X(01)00002-3","article-title":"Gpr85, a novel member of the G-protein coupled receptor family, prominently expressed in the developing mouse cerebral cortex","volume":"1","author":"Hellebrand","year":"2001","journal-title":"Gene Expr. Patterns"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrd4052","article-title":"Emerging paradigms in GPCR allostery: Implications for drug discovery","volume":"12","author":"Wootten","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.coph.2017.01.001","article-title":"Recent advances in drug discovery of GPCR allosteric modulators for neurodegenerative disorders","volume":"32","author":"Lutjens","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1756-6606-6-48","article-title":"Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1","volume":"6","author":"Notartomaso","year":"2013","journal-title":"Mol. Brain"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/mds.26659","article-title":"A phase 2a trial of the novel mglur5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson\u2019s disease","volume":"31","author":"Tison","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_181","first-page":"183","article-title":"Activation of M1 and M4 muscarinic receptors as potential treatments for Alzheimer\u2019s disease and schizophrenia","volume":"10","author":"Foster","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_182","first-page":"2838","article-title":"Allosteric modulation of muscarinic acetylcholine receptors","volume":"3","year":"2010","journal-title":"Pharmacological"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1021\/acs.jmedchem.6b00544","article-title":"Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects","volume":"59","author":"Davoren","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.drudis.2013.09.005","article-title":"Allosteric modulation of the M1 muscarinic acetylcholine receptor: Improving cognition and a potential treatment for schizophrenia and Alzheimer\u2019s disease","volume":"18","author":"Melancon","year":"2013","journal-title":"Drug Discov. Today"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1021\/acsmedchemlett.6b00461","article-title":"Discovery of VU0467485\/AZ13713945: An M4 PAM evaluated as a preclinical candidate for the treatment of schizophrenia","volume":"8","author":"Wood","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nature17188","article-title":"Crystal structures of the M1 and M4 muscarinic acetylcholine receptors","volume":"531","author":"Thal","year":"2016","journal-title":"Nature"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.npep.2018.07.001","article-title":"Sirtuin 1 and Alzheimer\u2019s disease: An up-to-date review","volume":"71","author":"Rizzi","year":"2018","journal-title":"Neuropeptides"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3389\/fimmu.2019.01000","article-title":"Regulation of Toll-Like Receptor (TLR) Signaling Pathway by Polyphenols in the Treatment of Age-Linked Neurodegenerative Diseases: Focus on TLR4 Signaling","volume":"10","author":"Azam","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/jnr.23421","article-title":"Cilostazol suppresses beta-amyloid production by activating a disintegrin and metalloproteinase 10 via the upregulation of SIRT1-coupled retinoic acid receptor-beta","volume":"92","author":"Lee","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1523\/JNEUROSCI.2369-17.2018","article-title":"SIRT1 deacetylates tau and reduces pathogenic tau spread in a mouse model of tauopathy","volume":"38","author":"Min","year":"2018","journal-title":"J. Neurosci."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"104490","DOI":"10.1016\/j.neuint.2019.104490","article-title":"The adenosine A2A receptor antagonist SCH58261 reduces macrophage\/microglia activation and protects against experimental autoimmune encephalomyelitis in mice","volume":"129","author":"Chen","year":"2019","journal-title":"Neurochem. Int."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Li, C., Wu, X., Liu, S., Zhao, Y., Zhu, J., and Liu, K. (2019). Roles of Neuropeptide Y in Neurodegenerative and Neuroimmune Diseases. Front. Mol. Neurosci., 13.","DOI":"10.3389\/fnins.2019.00869"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e636","DOI":"10.1038\/cddis.2013.160","article-title":"Neuropeptide Y receptors activation protects rat retinal neural cells against necrotic and apoptotic cell death induced by glutamate","volume":"4","author":"Elvas","year":"2013","journal-title":"Cell Death Dis."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1074\/jbc.M115.678185","article-title":"Systemic central nervous system (CNS)-targeted delivery of neuropeptide Y (NPY) reduces neurodegeneration and increases neural precursor cell proliferation in a mouse model of Alzheimer disease","volume":"291","author":"Spencer","year":"2016","journal-title":"J. Biol. Chem."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/j.1471-4159.2010.07154.x","article-title":"NPY promotes chemokinesis and neurogenesis in the rat subventricular zone","volume":"116","author":"Thiriet","year":"2011","journal-title":"J. Neurochem."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/fcp.12464","article-title":"Inflammatory process in Parkinson disease: Neuroprotection by Neuropeptide Y","volume":"33","author":"Pain","year":"2019","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_197","first-page":"23","article-title":"Neuropeptides and Microglial Activation in Inflammation, Pain, and Neurodegenerative Diseases","volume":"2017","author":"Carniglia","year":"2017","journal-title":"J. Mediat. Inflamm."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.brainres.2010.04.011","article-title":"Neurodevelopmental actions of leptin","volume":"1350","author":"Bouret","year":"2010","journal-title":"Brain Res."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1007\/s12035-019-1487-4","article-title":"Molecular Insights into NR4A2(Nurr1): An Emerging Target for Neuroprotective Therapy Against Neuroinflammation and Neuronal Cell Death","volume":"56","author":"Jakaria","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1007\/s12035-018-1420-2","article-title":"Nootropic and anti-Alzheimer\u2019s actions of medicinal plants: Molecular insight into therapeutic potential to alleviate Alzheimer\u2019s neuropathology","volume":"56","author":"Uddin","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Haque, M.E., Akther, M., Jakaria, M., Kim, I.S., Azam, S., and Choi, D.K. (2019). Targeting the microglial NLRP3 inflammasome and its role in Parkinson\u2019s disease. Mov. Disord.","DOI":"10.1002\/mds.27874"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3389\/fnmol.2018.00307","article-title":"Neurotoxic Agent-Induced Injury in Neurodegenerative Disease Model: Focus on Involvement of Glutamate Receptors","volume":"11","author":"Jakaria","year":"2018","journal-title":"Front. Mol. Neurosci."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/2\/506\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:01:02Z","timestamp":1760173262000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/9\/2\/506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,23]]},"references-count":202,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["cells9020506"],"URL":"https:\/\/doi.org\/10.3390\/cells9020506","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,23]]}}}